This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk13: Good morning. My name is Dexter, and I'll be your conference operator today. At this time, I would like to welcome everyone to the premiering fiscal year 2021 third quarter results and conference call. All I have in place on YouTube to prevent any background noise. After the speaker's remarks, there will be a question and answer session. As a reminder, this conference is being recorded. Ms. Angela Cade, you will begin the conference.
spk00: Thank you, Dexter. Welcome to Premier's Fiscal Year 2021 third quarter conference call. Our speakers this morning are Mike Alkire, our president and CEO, and Craig McCaffin, our chief administrative and financial officer. Before we get started, I want to remind everyone that our earnings release and the supplemental slides accompanying this conference call are available in the investor relations section of our website at investors.premierinc.com. Management's remarks today contain certain forward-looking statements. and actual results could differ materially from those discussed today. These forward-looking statements speak as of today, and we undertake no obligation to update them. Factors that might affect future results are discussed in our filings with the SEC, including our Form 10-Q for the fiscal third quarter, which we expect to file soon. We encourage you to review these detailed safe harbor and risk factor disclosures. Also, where appropriate, we will refer to adjusted or other non-GAAP financial measures, such as free cash flow, to evaluate our business. Reconciliations of non-GAAP financial measures to GAAP financial measures are included in our earnings release, in the appendix of the supplemental slides accompanying this presentation, and in our earnings form 8K, which we expect to furnish to the SEC soon. I will now turn the call over to Mike Alkire.
spk09: Thanks, Angie. Good morning, everyone, and thank you for joining us today for our discussion of our fiscal 2021 third quarter results, outlook for the remainder of this fiscal year, and preliminary thoughts on fiscal 2022. Before we get started, let me say that I'm honored and humbled to have been chosen by our board to lead Premier as we continue on our strategic journey to transform healthcare together with our members I want to thank Susan for her leadership and her role in shaping Premier into the company it is today, an industry-leading healthcare solutions company with an extensive provider network and artificial intelligence-enabled technology platform that helps our members and other customers to deliver and provide access to higher quality, more cost-effective healthcare. Susan and I continue to work closely to ensure a smooth transition, and I look forward to her continued insights and perspectives for Premier, as she takes on her advisory role. Turning to some highlights for the third quarter, we are pleased with our results, which exceeded our expectations and reflect another quarter of strong fundamental performance. Compared with the third quarter of fiscal 2020, consolidated net revenue grew 40%, supply chain services segment net revenue increased 56%, and performance services segment net revenue grew 3%. As we expected, adjusted EBITDA and adjusted earnings per share declined year over year, primarily due to the amended and extended GPO agreements that were executed in August 2020. We also announced this morning that we are increasing our fiscal 2021 guidance ranges. We currently expect consolidated net revenue to be in the range of 1.671 to $1.711 billion. adjusted EBITDA to be in the range of $460 to $475 million, and adjusted EPS to be in the range of $2.42 to $2.51. Craig will discuss our financial results and updated guidance in his remarks. This morning, as I take on the role of Premier's new CEO, I want to share with you my view of our business and our path forward. With my background in technology, a long history in process improvement, and a commitment to Premier's vision, mission, and values, I am focused on leading Premier's continued evolution into a technology-based healthcare solutions provider. We will use our differentiated network, vast data, and machine learning to help our members and other customers deliver higher quality, lower cost healthcare, and reduce waste and other inefficiencies. This is something that I'm very passionate about, and as part of my plan, I'm focused on three key priorities as we advance our strategies to achieve our goals and to deliver long-term growth and value to our stockholders, members, and other stakeholders. First, we are reinforcing our focus on our mission, vision, and values and enhancing our culture with a mindset of innovation, growth, discipline, and accountability. This includes executing and delivering consistent operational and financial performance. Second, we are continuing to nurture our core business while expanding into adjacent markets and diversifying our business. We believe our strong relationships with our members also position us to serve the needs of employers, payers, and life sciences companies through our data and technology. Third, we will be more creative in our approach to increasing the value of our portfolio of unique assets, This includes building, acquiring, enhancing, and refining the right complement of assets and capabilities. Our recent acquisition of Invoice Delivery Services, a leading provider of electronic invoicing and payment solutions for healthcare, is an example of this approach. Adding the IDS capabilities to digitize and automate invoicing and payments to our technology portfolio of assets is a key component in advancing our strategy to tech enable all aspects of the supply chain. We believe these capabilities will further diversify and grow our revenue streams by accelerating our expansion of technology-enabled financial solutions for healthcare. We also expect these capabilities will give us greater visibility to total member spend in the GPO, which will enable us to continue to identify GPO contract expansion opportunities and drive further contract compliance. In addition, IDS provides an opportunity for us to use advanced technology to help our members reduce the total cost of care by enhancing invoice and payment workflow and enabling automated communications between contracted parties. Over the past several years, we have strengthened our foundation, one that positions us well for the opportunities that are ahead of us. We have longstanding strategic relationships with our members. with access to what we believe is one of the industry's largest repositories of healthcare data, including clinical, financial, and operational data. We've enhanced our integrated technology platform by expanding our natural language processing capabilities, which provide real-time and actionable insights at the point of the physician decision-making to reduce variations in care and safely reduce costs. We have further expanded our use of artificial intelligence to begin solving for new use cases in adjacent markets, including the identification of patients for clinical trials and the modernization of manual and costly processes such as prior authorization. We have a strong leadership team with a significant industry experience in their respected areas of expertise. And we continue to operate from a position of financial strength, as reflected by our financial balance sheet our free cash and our free cash flow generation. Under my leadership, we will look forward to further accelerate technology enablement to advance our strategies. Our members and our customers and other adjacent markets are now being confronted with new expectations and requirements in an environment that will require technology enablement to help drive higher quality healthcare through improved health outcomes with efficiency and lower cost. Premier is a critical partner in helping to navigate this new environment and address these necessary evolution into the future. I'll now discuss a review regarding some of the anticipated changes in Washington, DC. While the Biden administration and Congress remain focused on ending the pandemic, attention is transitioning to economic recovery. This includes healthcare reforms to expand coverage and improve healthcare quality and cost effectiveness. First, We anticipate an improved reimbursement environment for our hospitals and health system members, which may result in a greater ability and willingness for them to take or to make incremental investments in technology and services to improve quality and reduce costs. Second, there is an increased focus on value-based care and pricing transparency, including incentives to move to risk-based alternative payment models. We believe we are well positioned to support our members through analytics capabilities that support evidence-based care and performance improvement. Third, there is a strong bipartisan support for automating the healthcare system's antiquated prior authorization system. We believe we are well positioned to support our members and other customers through our current prior authorization solutions. And then finally, we expect action to create a technology-enabled resilient U.S. healthcare supply chain. Premier has already taken steps, many in partnerships with our members, to meet these needs, and we look forward to further partnering opportunities to improve healthcare supply chain resiliency. In summary, we are very pleased with our third quarter results. The role we continue to play in supporting our members through the pandemic and our progress towards achieving our multi-year strategic goals. As we look forward, we are focused on operational and financial execution, advancing our strategy, and delivering meaningful solutions to our members and our other customers to create long-term value for all of our stakeholders. I will now turn the call over to Craig McKesson for a discussion of our financial performance and expectations.
spk08: Thanks, Mike. I'll begin with a brief discussion of our fiscal 2021 third quarter results and provide details regarding our updated financial guidance for the remainder of fiscal 2021. We are pleased with our strong performance in the quarter and we're excited about the opportunities ahead of us. While we are still developing our fiscal 2022 plan, I will also provide you with our preliminary thoughts for next fiscal year. For the third quarter of 2021, Consolidated net revenue of $469.9 million increased 40% from the year-ago quarter. Supply chain services segment revenue of $371.2 million increased 56% compared with the prior year quarter, and performance services segment revenue of $98.7 million increased 3% compared with the prior year quarter. In supply chain services, Net administrative fees revenue decreased compared with the prior year quarter primarily due to, one, as we expected, our amended and extended GPO agreements, which were effective July 1, 2020, and reduced net administrative fees revenue by approximately $32 million in the third quarter compared with the prior year quarter. Two, the impact of the $5 million in GAAP-required non-cash amortization of prepaid contract administrative fees as a result of our prior year asset acquisition of Acurity and Nexera in February 2020, and three, the ongoing impact on net administrative fees revenue from the COVID-19 pandemic. Demonstrating the resiliency of our core business, these items were partially offset by growth in net administrative fees revenue as a result of the ramp up from the addition of new members including Virginia Mason Health System and Community Healthcare System, and ongoing contract penetration, driven in part by our high compliance portfolio programs and the addition of new contract categories and suppliers across both our acute and alternate site businesses. Products revenue increased 253% from the prior year quarter, primarily driven by $155 million in incremental revenue related to growth in commodity products and aggregated purchase of certain other products, as well as our ongoing success in securing PPE and other critically needed high-demand supplies for our members as a result of the COVID-19 pandemic. The growth in product revenues, while low margin, given our commitment to deliver high-quality and low-cost products to members in need, has delivered incremental profitability to mitigate the negative impact on our GPO, resulting from declines in utilization and spend during the pandemic. In our performance services segment, revenue growth in the third quarter was primarily driven by $5 million in incremental revenue in our Contigo health business, related to our acquisition of Health Design Plus in May 2020, as well as growth in our applied sciences, cost management, and performance improvement consulting businesses. These increases were partially offset by lower revenue associated with enterprise analytics license agreements during the current period compared with the prior year period, which included significant revenue from enterprise analytics license agreements entered into during the prior year quarter. With respect to profitability, GAAP net income was $51.4 million for the quarter. As we expected, consolidated adjusted EBITDA of $121.2 million in the third quarter decreased 22% from the prior year quarter, primarily due to supply chain services adjusted EBITDA of $117.9 million, which decreased 21% quarter over quarter, mainly as a result of the amended and extended GPO agreements and the non-cash amortization of the Acurity prepaid administrative fees. This decline was partially offset by performance services segment adjusted EBITDA of $36 million, which increased 4% from the prior year quarter. Adjusted net income of 78.5 million decreased 12 percent from a year ago, and adjusted earnings per share decreased 12 percent to 64 cents. Our effective tax rate of 22 percent, which we now expect for the remainder of fiscal 2021, was slightly lower than we previously anticipated and primarily results from the release of a valuation allowance on deferred tax assets associated with current year utilization of historical net operating losses. This change in the effective tax rate resulted in a two cent benefit to our diluted earnings per share in the third quarter and five cents for the nine months ended March 31, 2021. From a liquidity and balance sheet perspective, cash flow from operations for the nine months ended March 31, 2021 was 192.4 million compared with $248.1 million for the prior year. The decrease was primarily due to expected lower net administrative fees revenue as a result of the amended GPO agreements and the impact of the COVID-19 pandemic. In addition, changes in working capital, including higher levels of inventory, primarily driven by the impact of aggregated purchasing of PPE as a result of the pandemic, also impacted net cash from operating activities. Free cash flow for the nine-month period ended March 31, 2021, was 91.6 million, compared with 213.9 million for the same period a year ago. The decrease, as we expected, was primarily due to the same factors that impacted net cash provided by operating activities, as well as payments made to former limited partners of Premier LP in connection with the early termination of the tax receivable agreement as a part of the company's restructure in August 2020. These factors were partially offset by the elimination of tax distributions to limited partners also resulting from the restructure. On April 23rd, 2021, Premier's Board of Directors declared a quarterly cash dividend of 19 cents per share payable on June 15th, 2021 to stockholders of record as of June 1st. Cash and cash equivalents totaled $132.6 million at March 31, 2021, compared with $99.3 million at June 30, 2020. Our five-year, $1 billion revolving credit facility had an outstanding balance of $200 million as of March 31st, and subsequent to quarter end, we repaid $75 million of that balance. In addition, we're excited about our March 2021 acquisition of IDS. These capabilities are operational, although still in their early stages, and we expect to make incremental investments over the next year or so to further build out the technology. Our goal is to have enhanced functionality fully operational to our members and suppliers over the next 12 to 24 months. We currently believe this capability will deliver $50 to $100 million in revenue over the next three to five years with meaningful profitability and will deliver a double-digit return on invested capital. As Mike highlighted earlier, with our increased visibility on the remainder of this fiscal year, we are updating our fiscal 2021 full-year guidance which is based on our year-to-date performance through March 31, 2021, and our current expectations for the remainder of this fiscal year. Our guidance incorporates certain key assumptions related to our business and the healthcare market, and consistent with prior years, it does not incorporate the effect of any future significant acquisitions that we may undertake. We are making the following updates to our guidance. We are increasing supply chain services segment net revenue to $1.3 to $1.33 billion, primarily comprised of GPO net administrative fees revenue of $565 to $580 million, and direct sourcing products revenue of $700 to $720 million. We are narrowing the range for performance services segment net revenue by increasing the low end of the range for a new range of $371 to $381 million, representing 7 to 10 percent growth over prior year. Together, these produce an increase in expected consolidated net revenue to a range of $1.671 to $1.711 billion. We are increasing adjusted EBITDA to be in the range of $460 to $475 million, as well as adjusted earnings per share to be in the range of $2.42 to $2.51. Our fiscal 2021 guidance is based on the following assumptions. We continue to expect that GPO net administrative fees revenue may continue to be pressured by lower overall healthcare utilization, the potential deferral of certain elective procedures, and the ongoing lower level of purchasing in non-healthcare-related areas as a result of the COVID-19 pandemic. We currently expect direct sourcing products revenue to decrease sequentially by approximately $10 to $20 million in the fourth quarter from the third quarter of fiscal 2021, with a further step down anticipated in fiscal first quarter 2022 as demand for certain PPE products subsides as a result of lower overall use, as well as a result of many of our members completing the buildup of their stockpiles of PPE and other critically needed items. As we have communicated previously, due to the timing and magnitude of enterprise analytics license agreements in our performance services segment, there will be periodic variability in the recognition of the revenue and profitability associated with these engagements during any given fiscal year. We expect capital expenditures to be slightly lower than we originally anticipated and to now be in the range of $100 to $105 million for the fiscal year. Lastly, we now expect that adjusted net income for full fiscal year 2021 will reflect an effective tax rate of 22%. As we look ahead to fiscal 2022, we expect the effective tax rate to revert back to a more normalized level ranging between 23 to 27 percent. As always, we will continue to evaluate the appropriate tax planning strategies, and to the extent we are able or not able to leverage any opportunities, it could bring us to the lower end or higher end of the range, respectively. Finally, as Mike commented earlier, As we look forward to fiscal 2022, we remain focused on executing on the key priorities he laid out to further strengthen and position our business for long-term success and achieve our multi-year compounded annual growth rate targets of mid to high single digits, excluding the impact of the COVID-19 pandemic for consolidated net revenue, adjusted EBITDA, and adjusted earnings per share. We are still in the process of finalizing our fiscal 2022 plan. Importantly, during the past year, we have been focused on taking actions that will drive our performance in fiscal 2022 and beyond. Our initial view for fiscal 2022 is to target mid- to high-single-digit growth in consolidated net revenue and to be near the low end of our multi-year compound annual growth rate targets of mid to high single digits for adjusted EBITDA. This will be driven in large part by two factors. First, the incremental impact on net administrative fees revenue from the restructuring in August 2020 as a result of the remaining members that did not agree to amended GPO agreements, which will result in a fee share at the higher end of the high 40s to low 50s percent range that we previously guided to. And second, some incremental investments to drive future growth. We currently expect profitability growth to perform at a higher level in our targeted range in subsequent years as our solutions gain further traction across our members and other customers. We expect to provide full-year fiscal 2022 financial guidance on our fourth quarter earnings call. We remain very excited about near and longer-term opportunities across our businesses. Thank you for your time today. Dexter will now open the call up for questions.
spk13: Thank you, Mr. Gray. As a reminder, to ask a question, you will need to press star one on your telephone. To withdraw your question, press the pound key. Again, that's star one to ask a question. Please stand by, we'll compile a Q&A roster. Your first question comes from the line of Anne Samuel from J.P. Morgan. Your line is open. Thanks so much for all the color and congrats on the great quarter.
spk04: I was hoping maybe you could provide a little bit more color on the increased focus on value-based care. What's the appetite looking like with your customer base to align with that? And what incrementally are you seeing out there in the marketplace?
spk09: Yeah, this is Mike. So it's interesting. So with the new Biden administration, it's a little too early to tell. But obviously we're really encouraged by the commentary and the actions that are coming out of D.C. And, you know, as you know, we've positioned the business to be a bit more agnostic where we're not, you know, so reliant on value-based care. But the net of everything is it's a little early to tell, but I think the signs are positively pointing towards more value-based care.
spk04: Very helpful. Thank you.
spk09: Thank you.
spk13: Your next question comes from the line of Jay Landrosy from Credit Suisse. Your line is open.
spk12: Yeah, thank you and good morning and congrats and good quarter. I want to get some color around, you know, community healthcare system partners contract when you announced a few days back, a few weeks back. My understanding is it was a win from Interlayer GPO. Just wondering if it was a fallout from the vision's acquisition of Interlayer And if you're seeing or expecting some additional opportunities from emerging from that combination.
spk09: Yeah, I think, Jalinda, you're referring to community health. So just as a quick reminder, that was a broad-based win for Premier, where I think obviously our GPO and our pricing played a significant role in us winning that opportunity, as well as our you know, the future and what we've actually been implementing from a technology standpoint to really get after all of the costs in the supply chain to include purchase services and some of the areas that we, you know, that GPOs don't historically focus on. But I think it was a win that really highlighted the differentiation that Premier has.
spk12: Okay. And then last comment Craig just made about this when you see in fiscal 22 about the some contracts which were not negotiated for a fee sharing previously. Can you quantify the impact? How much is that? And with that, will you be done with all the contracts coming in the, you know, that high 40, low 40 fee sharing arrangement? Just give us more color there.
spk08: Craig Allstarth, Sure. This is Craig Allstarth, and then Mike can add any color. You know, as we talked about when we did the restructuring in August of 2020, the vast majority of our members agreed to the amended and extended GPO agreements, but we did have a subset that were continuing or already in sort of an evaluation process. They continued under the existing contracts that we had in place prior to the restructuring for this fiscal year, and so we've been working with them. The majority of them will have new agreements in place moving forward. There have been a very small subset that have, through the process, made a determination to partner with a different organization due to leadership change or merger acquisition. But we're not at a point to actually specifically quantify the magnitude, but it will have an impact on our growth next year and cause that fee share to move within the original range, but from the high 40s to the low 50s.
spk09: Yeah, Craig, the only thing I'll add is that, you know, we are very disciplined about, you know, the economics that we, you know, provide to customers. And there are times when, from a business standpoint, it does not make sense to, you know, continue the partnership. So we, you know, we will walk away if, in fact, we're not getting the economics that make sense for our business. Okay. Thanks, guys.
spk13: Your next question comes from the line of Ryan Daniels from . Your line is open.
spk01: Hey, good morning. This is Jared for Ryan. Mike, I wanted to circle back to one of the points that you talked about in the prepared remarks just around some of the market adjacencies that you're looking to expand into. Yeah, I know we've talked a good deal about, you know, the employer and the life sciences. I think those have been themes in the last couple of quarters. So I was hoping maybe we could spend a little bit more time around the payer segment that you mentioned. You know, just curious if you could talk a little bit further about kind of where you see Premier sitting from a value proposition perspective for that channel. I know you talked a little bit about prior authorization, so maybe there's some value add on that front, but you're just curious if you could talk about So any areas where you see Premier adding value and any specific investments or product areas that you think Premier can add to further penetrate that adjacent market?
spk09: Sure. Thanks for the question. So from a payer perspective, I think there's two areas that – and you mentioned one of them – that I think our technology and our data and our network lends themselves well to providing valuable services to. So first – We believe that in the prior authorization space, as you suggested, using our natural language technology to literally embed things into the workflow or insights into the workflow is something that payers are going to be very supportive of. And I think you're aware that one of the initiatives that we're currently working on is for Medicare, which is all about PAMA, which is a focus on looking at ways to reduce high-cost imaging. So just think of the potential extension of high-cost imaging and other diagnostics into the payer market. So I think that's number one. Number two, we have a number of our healthcare systems that actually have health plans. So from that standpoint, many of them are very, very interested in linking into our Contigo Health Initiative. as they think about, you know, how do they create a more meaningful, capable health plan to their communities and create, you know, or leverage wrappers for when their health plan participants need services outside of their current geographic arena. So I think in two ways, one prior off and then obviously leveraging our Contigo health offerings.
spk01: Got it. That makes sense. And thanks for that. And then maybe just a quick follow up. And I think this is maybe more for Craig. Could you just talk a little bit to what extent your sales and implementations and business development activities kind of remain split between sort of virtual or remote or in person? You're just trying to get a sense of what kind of normalized OpEx might look like and to what extent that might also be impacting the commentary that you shared regarding fiscal 22 profitability.
spk08: Sure, I'll start, and then, again, Mike can add color as well. You know, from a standpoint of virtual versus on-site, we certainly have some of our advisory services and our field force that have begun to go back on-site to our facilities but continue to do a fair amount in a virtual capacity as well. And I think the go-forward business will be a mix of that on a prospective basis, I would expect. I would say that as we look to next year, we do expect to see some incremental OPEX as continued travel starts to pick back up, as we do begin to reconvene with our members in person, in aggregate, which we have done virtually this year. So certainly that is an impact on our fiscal 2022 performance as we return to normal. But overall, continue to begin to be more on site with our members, but we'll also leverage the opportunity for virtual enhancement that I think has been learned across the industry through the pandemic.
spk01: Okay, great. That makes sense. And thanks and congrats on the quarter. Thank you. Thank you.
spk13: We have a question from Richard Close from Canada College of Unity. Your line is open.
spk10: Great. Thanks. Congratulations on the quarter. Mike, I was curious if you could expand a little on your comment that you need to be creative in your approach to increasing value of the portfolio assets. Is there anything specific that you can add to that or just like where are you coming from in terms of that statement?
spk09: Yeah, I, first of all, um, You know, we've been doing a lot of it over, you know, the last couple of years where we're looking for partners and others to really help extend our capabilities. So as you think about our future going forward and as we're, you know, continuing to evolve into new markets, you know, we are going to be looking for, you know, partners to literally help us, you know, expand in those markets either, you know, quicker or with more scale. So think of, you know, maybe organizations within life sciences that have, you know, strong ability, you know, from a channel standpoint. Or think of organizations that can marry data that they have maybe from a claim standpoint with some of our clinical as well as our operational data. You know, so think of, you know, also maybe in the – prior off areas that we're looking also for partners that have clinical protocols that we can embed into some of our machine learning and natural language technologies. So those would just be a couple of examples.
spk10: Okay, and then as we think about acquisitions and new product development, Is there any sort of guideposts you can provide us in terms of how much is focused in on the core business versus the new adjacent markets?
spk08: Sure, Richard. This is Craig. I don't know that we'd say we have a specific earmark. Broadly, I think we will always look for capabilities to enhance our core business technology capabilities. So on the supply chain side, things that we can do to further cement the technology evolution of our supply chain services and drive additional contract penetration and access to product suites, et cetera. On the performance services side, I think relative to the core provider component of the business, we'll continue to look for ways to improve and enhance the data across the entire continuum of care. But we will also focus on opportunities to extend, and as Mike just talked about, look for those partnerships or potential M&A targets to further enhance our growth opportunities in the life sciences, payer, and employer markets, although those do tie very directly to our kind of core capabilities in improving provider performance.
spk10: Okay, thank you.
spk13: Your next question comes from the line of Jessica Tassin from Piper Sandler. Your line is open.
spk03: Hi, thanks for taking the question. It's Jess on for Sean. I think we were just interested if you could remind us what the net admin fee impact of the security and Nextera transactions was that we are lapping in February of 2021. And then just any other P&L impacts of those transactions that we should be aware of as we lapped them.
spk08: Sure. So from a standpoint of the Accuracy Index acquisition, we've disclosed the fact that prior to our acquisition of that business, they had entered into some agreements with a prepaid administrative fee that we were required to report from a GAAP standpoint in that way. That's about $20 million a year. So we've been having the impact of that amortization of about $5 million per quarter in non-cash amortization. Now that we're a year past should be lapped in terms of that impact as we move forward. And then, again, they had entered into five-year agreements with the vast majority of their members prior to the acquisition, so we're in place with them moving forward. And then for the rest of our business, the majority of our members entered into five-, six-, and seven-year contracts at the increased fee share that we've previously disclosed. We had talked about $100 to $110 million or so impact to our fiscal 2021 results, that as we move into fiscal 22, we will be beyond, although we do have the small minority of members that I talked about in my prepared remarks, where either some of them will have incremental fee shares, they've been operating under the historical 30% that all of our members had prior to the restructuring, and then we have had a couple of Again, that potentially will not or have made a decision to no longer remain with Premier as a result of either executive changes within that healthcare system or due to merger and acquisition. We had a couple that were acquired, as happens in a consolidation environment. But again, largest percentage of our members, you know, 96% agreed to the amended and extended GPO agreements moving forward.
spk03: Got it. And can I just follow up and ask, what's your opinion on some of the strength and performance services in the quarter? And should we expect that those are multi-month contracts or kind of shorter term in nature? Any color would be helpful.
spk09: Yeah. In general, our Health Design Plus acquisition is obviously going well. We're continuing to see a lot of strong interest in our advisory services and our clinical decision support, and our life sciences business had a really solid quarter this quarter.
spk08: Yeah, and I think this is Craig, just a little bit of color. So with respect to the applied sciences growth, that's a combination of what we would call sort of short-term data projects where we actually deliver data, and they delivered strong growth, and then kind of ongoing consulting projects, so it's really a mix of short-term and kind of more extended agreements. I will say we continue to have a very positive pipeline of new engagements and continue to see really strong growth in the applied sciences part of our business. As Mike mentioned, in the performance improvement consulting arena, those are primarily engagements that they're not one-time episodic. They tend to be consulting engagements to deliver margin improvement services over a period of time. And again, seeing really strong growth and performance in that part of the consulting practice. And so just it's a blend of sort of as is typical, kind of more short-term engagements that deliver revenue in the quarter, and then with extension beyond into the next quarter and beyond.
spk00: Okay.
spk13: Okay. Your next question comes from the live Irish from Barenburg. Your line is open.
spk11: Hi, good morning. Thanks for taking my question. Um, so along the same line on live sciences, I'm just wondering if you can kind of speak about the opportunities there. So Mike, you mentioned in the remarks that, um, you guys have clinical trial recruitment. Maybe can you talk about that business a little bit? And then, um, Also, can you kind of help us to understand what's the competition like for your life sciences business?
spk09: Sure. So this is Mike. I'll start. So just as a reminder, you know, our life sciences business obviously is focused for the most part towards the pharmaceutical industry, but we do do some things with the medical device area as well. I think our sweet spot really is all around real-world evidence. So as You know, new discoveries are being made. I think pharma and med device partners really like a warm test bed, if you will, post, you know, drug approval to see how therapies are actually reacting in the real world. Because we have a very, very strong network, because we have very, very strong data, that provides them insights into, you know, how to effectively, you know, how to effectively leverage those therapies into the patient markets. So that's number one. Number two, and this is sort of a recent trend, we're also beginning to work with Life Sciences Company because we have the ability at the point of care to look at the unstructured data to identify whether or not patients would be good for specific drug trials. And so there's a lot of interest on behalf of of pharma to understand the utilization of that technology and identify whether or not a patient has a good prospect of being a good candidate for a trial. So we think that there's pretty significant upside from a drug trial patient identification standpoint. As it relates to competitors, I think the very unique aspect or the strength of Premier is You know, basically the three items that Craig and I have been talking about, really, it's our strong both clinical and operational data. Two, it's our technology, our ability to use natural language technology, natural language processing, and embed information or glean information from the electronic medical record. And it's also our strong network that we have with our health systems. with its ability truly to, you know, at a broad-based standpoint, be able to look at real-world studies and those kinds of things.
spk11: Okay, great. And then my follow-up question is on performance services. So it sounds like the lower enterprise analytics licensing revenue is entirely due to timing. Is that right? And then maybe can you kind of talk about your bookings and maybe pipeline for that enterprise analytics solution?
spk08: Sure. This is Craig. So, yes, whenever we enter into an enterprise analytics license agreement, which we continue to really like because it furthers the sort of strategic alignment with the member and the long-term stickiness of that relationship, But the way the revenue recognition does work is that the majority, a large portion of the contracted revenue gets recognized at the time of that engagement. And so there is a timing implication that's going to happen. We did have enterprise analytics license agreements in the current quarter. It's just not at the level that we had had in the prior year quarter. So it did present a little bit of a headwind in Q3. But in prior quarters earlier in the year, we had strong growth from those From a pipeline standpoint, there continues to be a pipeline for those engagements and relationships moving forward. It's just hard to predict, Iris, exactly what quarter something may hit in terms of how that pipeline develops over time.
spk11: Okay, thanks.
spk13: Next question, Bill Sutherland with Benchmark Company.
spk07: Thanks, and good morning, everybody. In performance services, with the growth and additions you've made to that portfolio of businesses, I wonder if you could give us a feel now for the mix of revenue between Perpetual and SAS and also tech-enabled services.
spk08: Sure, Bill. This is Craig. So we continue to have about 70% of the business today being technology-based, which is a combination of both the SAS and the license-based revenue that we've discussed tied to enterprise analytics license agreements, and about 30% of our business is in the advisory services, either I'll say one-to-one margin improvement services that we provide or the collaboratives that we have, which think of as one-to-many consulting where we're working on a collective issue. such as bundled payment or some other aspect of value-based care that we continue to have in that portfolio as well.
spk07: And then, Craig, within the 70%, roughly what would be the split with Perpetual and more SaaS-like?
spk08: The significant majority today continues to be SAS-based revenue, but we have had a ramp-up in enterprise analytics license agreements over the past year or so, so it has become more of a piece, but the vast majority is still SAS-based.
spk07: Okay.
spk08: That's exactly what I was wondering.
spk07: And then finally, regarding Stamson, Mike, did you say that the use case there with PAMA Is that a needle mover in this next fiscal year? Should we think of it that way?
spk09: I think it's all embedded in our, you know, our forecasts and our guidance.
spk07: For fiscal 22?
spk08: Yeah, right now. Well, we haven't issued guidance for fiscal 22 yet, but included in the mid to high single-digit revenue growth that we've contemplated and said we intend to target for next year, that factors in some incremental contributions from that part, that expansion of our business.
spk09: Okay. Thanks, everybody. Thank you.
spk13: Next is Stephanie Davis with SEB Ring. Your line is open.
spk02: Thank you for taking my question. Congrats on the quarter. I want to follow up on the real world evidence questions, just given we're seeing a lot of different players with data sets start to enter the side of the universe. Could you walk us through the competition dynamics? Is this something where a life sciences company would have solely one data set or would it be kind of a coopetition where multiple data sets can coexist in peace? So there's not as much need to differentiate.
spk09: Yeah. You know, A couple things. First of all, I said earlier in our remarks that we've got some incredible data sets, right? So we have, if you think about our clinical data sets, we have more than 1,000 hospitals that subscribe to our clinical data sets, about 1,000 hospitals in our safety. As you think about, you know, you just heard the clinical decision support and Stanton Health We're in hundreds of hospitals where we're getting sort of real-time feeds back and forth with Epic and Cerner in Athena. You think about our operational labor data sets, again, we have close to 1,000 hospitals that participate there. So we just think we've got a very, very strong, capable data set that's very, very unique in the industry. And now, most recently, with some of the work that we've been doing with a couple of our members, we're now beginning to pull in claims data as well. So I think our history of integrating these data sets and creating meaningful insights out of these data sets are truly things that differentiate us. And then our ability truly to take those data and write them into the workflow in terms of the insights or to pull information out of that the workflow or from the electronic medical record, it's a pretty significant differentiation for our capability and for life sciences.
spk02: And then thinking about the use cases for having this robust data set in a post-COVID world, is it more towards analytics? Is it more towards improving efficiencies, staffing, modeling? What are you seeing the demand?
spk09: Yeah, so post, thank you, that's a great question. So post-COVID for our health systems, it's all about getting back to normalcy. So obviously, as they're, you know, as COVID is, in many cases, is, you know, on the downward swing, they're trying to get, you know, as many elective procedures, you know, back up and running as quickly as possible. Many of our healthcare systems are coming to us and asking us to help them to create a more flexible corporate cost structures using our data and be a bit more, you know, dynamic with those cost structures and asking us to provide services and those kinds of things to augment them when they need help or to help them when they, you know, need to reduce costs. So I think, number one, from a healthcare system standpoint, it's really all about helping them get back to some form of normalcy. Life sciences, as Craig and I have both been talking about, I think that... Real world evidence is continuing to be a significant opportunity for us. Patient identification for drug trials and those kinds of things also seem to be obviously a much, the life sciences companies are very interested in that as well. And then finally, from a Contigo standpoint, you have many of our large employer customers that you know, have experienced some, you know, financial turmoil as a result of COVID, and they're looking for ways to maximize the investment in healthcare for their employees. And so they're looking for our Contigo offering to sort of help them, you know, migrate through some of those scenarios to ensure that you know, they can work more closely with our health systems and get the lowest cost, highest quality care possible.
spk02: Sounds like a good setup. Thank you, guys.
spk09: Thank you.
spk13: Next question is from Mike Chenery from Bank of America.
spk06: This is Alan in for Mike. Thanks for taking the questions. Craig, I think you mentioned the direct sourcing business, some of the PPE you expect to see a step down over the next couple quarters. Can you talk about what you're hearing from clients and what you see the demand curve looking like out a couple quarters?
spk08: Sure. So I think as I mentioned in my prepared remarks, you know, demand certainly as COVID has become a bit more stabilized is coming down, although I will say it depends on kind of region and geography. I mean, we are continuing to see sort of pretty significant wave in the upper Midwest. So in that part of the country, we are continuing to see demand, but in many other parts, as you're well aware from everything you're seeing in the news, you know, COVID cases are down dramatically. And I think that people have become far more effective at sort of managing that in an appropriate fashion. The other point that I highlighted that I think is important is that a lot of health systems have spent the past year ensuring they have appropriate stockpiles of critically needed PPE and other equipment so that they're not put into a similar predicament as happened a year ago when they were down to the hour in terms of some of that supply. And so we think that that's been built up, and we will get back to more of a normalized trend. So as I articulated, we see a slight step down in Q4, $10 million to $20 million step down off of what we had in the third quarter, and then do expect a pretty significant step down moving into fiscal 2022 from the levels that we're at at this point. We're still sort of working through the exact sequential impact of that over multiple quarters, and I think we'll have more color to that when we actually establish and issue guidance in August.
spk06: Great. Thank you.
spk13: There are no further questions at this time. I would like to turn the conference back to Mr. Mike Hawkins.
spk09: Thank you, Dexter, and thank you all again for joining our call this morning. I look forward to engaging with you in the weeks and months ahead and sharing with you the progress we're making on achieving our goals.
spk13: This concludes today's conference call. Thank you for all joining. You may now disconnect.
Disclaimer